Search
Ethanolamine oleate
go.drugbank.com/drugs/DB06689ApprovedEthanolamine oleate is a mild sclerosing agent. … It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.
Categories: Compounds used in a research, industrial, or household setting, Sclerosing Agents for Local InjectionStrontium chloride
go.drugbank.com/drugs/DB13987ApprovedWithdrawnSrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168]. … Such strontium chloride toothpaste formulations may subsequently not be available for sale anymore in certain parts of the world [A33167, A33168].
Ertugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigational[A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621] … Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus.
Synonyms: 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose, β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-Categories: Drugs Used in DiabetesCapivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalTherefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalPrimary biliary cirrhosis, or PBC, is a progressive and chronic condition that leads to hepatic injury often resulting in end-stage liver failure that requires liver transplantation. … hepatic decompensation) due to a risk of liver failure, in some cases requiring liver transplantation.
Esketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigational[L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications … Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970.
Categories: Antidepressive Agents Indicated for Depression, Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor AntagonistsSynonyms: L-ketamineEfinaconazole
go.drugbank.com/drugs/DB09040ApprovedInvestigationalIt was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia. … Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy. … Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of [macitentan].
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763] … Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid].
Categories: Drugs for Treatment of Bone Diseases, Phospholipases A, antagonists & inhibitorsBexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigational[A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes. … [A256413] SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed in the kidney.
Categories: Drugs Used in Diabetes